Generic method approaches for monoclonal antibody therapeutics analysis using both ligand binding and LC-MS/MS techniques

Bioanalysis

Volumn 8, Issue 1, 2016, Pages 19-27

  Lee, Jean W ^a  

^a BioQualQuan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; LIGAND;

ANALYTIC METHOD; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CLINICAL STUDY; COMPUTER MODEL; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; NONHUMAN; RECEPTOR BINDING ASSAY; TANDEM MASS SPECTROMETRY; AMINO ACID SEQUENCE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, LIQUID; HUMANS; LIGANDS; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY;

EID: 84952690875     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.231     Document Type: Article

References (24)

1. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725 (2007).
2. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs 3(5), 422-430 (2011).
3. Lee JW, Kelley M, King LE, et al. Bioanalytical approaches to quantify total and free therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011).
4. White JT, Golob M, Sailstad J. Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. Bioanalysis 3(16), 1799-1803 (2011).
5. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. (2), 296-302 (2012).
6. Koren E, Smith HW, Shores E, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008).
7. Dubois M, Fenaille F, Clement G, et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal. Chem. 80(5), 1737-1745 (2008).
8. Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 134(5), 825-834 (2009).
9. Hagman C, Ricke D, Ewert S, et al. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatographytandem mass spectrometry. Anal. Chem. 80(4), 1290-1296 (2008).
10. Heudi O, Barteau S, Zimmer D, et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal. Chem. 80(11), 4200-4207 (2008).
11. Ji C, Sadagopan N, Zhang Y, Lepsy C. A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry. Anal. Chem. 81(22), 9321-9328 (2009).
12. Liu H, Manuilov AV, Chumsae C, Babineau ML, Tarcsa E. Quantitation of a recombinant monoclonal antibody in monkey serum by liquid chromatography-mass spectrometry. Anal. Biochem. 414(1), 147-153 (2011).
13. Li H, Ortiz R, Tran L, et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal. Chem. 84(3), 1267-1273 (2012).
14. Jenkins R, Duggan JX, Aubry A-F, et al. Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics. AAPS J. 17, 1-16 (2015).
15. Furlong Mt, Ouyang Z, Wu S, et al. A universal surrogate peptide to enable LCMS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc fusion protein drug candidates in pre-clinical animal studies. Biomed. Chromatogr. 26(8), 1024-1032 (2012).
16. Law WS, Genin J-C, Miess C, et al. Use of generic LC- MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. Bioanalysis 6(23) 3225-3235 (2014).
17. Furlong MT, Titsch C, Xu W, et al. An exploratory universal LC-MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. Bioanalysis 6(13), 1747-1758 (2014).
18. Anderson NL, Anderson NG, Haines LR, et al. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3, 235-244 (2004).
19. Bronsema KJ, Bischoff R, van de Merbel NC. Internal standards in the quantitative determination of protein biopharmaceuticals using liquid chromatography coupled to mass spectrometry. J. Chromatogr. B. 929(893), 8941-8914 (2013).
20. Hall MP, Gegg C, Walker K, et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J. 12(4), 576-585 (2010).
21. Hager T, Spah C, Xu J, et al. Differential ELISA and ligandbinding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal. Chem. 85, 2731-2738 (2013).
22. Li H, Ortiz R, Tran L, et al. Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing. AAPS J. 15, 337-346 (2013).
23. Timmerman P, Tiered approach: from plan into practice. Bioanalysis 6(5), 585-586 (2014).
24. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312-328 (2006).